SkinBioTherapeutics - Appointment of Joint Broker
Appointment of Joint Broker
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For more information, please contact:
Tel: +44 (0) 161 468 2760
Tel: +44 (0) 20 7213 0880
Turner Pope Investments (Joint Broker)
Tel: +44 (0) 20 3621 4120
Tel: +44 (0) 20 3861 6625
| || |
Tel: +44 (0) 20 7457 2020
Notes to Editors
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr.
SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer office of the
The Company joined AIM in
The Company is based in
This information is provided by RNS
Quick facts: SkinBioTherapeutics PLC
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE